These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1658 related articles for article (PubMed ID: 27910859)

  • 21. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
    Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
    World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topographical Distribution and Spatial Interactions of Innate and Semi-Innate Immune Cells in Pancreatic and Other Periampullary Adenocarcinoma.
    Lundgren S; Micke P; Elebro J; Heby M; Hrynchyk I; Nodin B; Leandersson K; Mezheyeuski A; Jirström K
    Front Immunol; 2020; 11():558169. PubMed ID: 33013928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
    Seifert L; Werba G; Tiwari S; Giao Ly NN; Alothman S; Alqunaibit D; Avanzi A; Barilla R; Daley D; Greco SH; Torres-Hernandez A; Pergamo M; Ochi A; Zambirinis CP; Pansari M; Rendon M; Tippens D; Hundeyin M; Mani VR; Hajdu C; Engle D; Miller G
    Nature; 2016 Apr; 532(7598):245-9. PubMed ID: 27049944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
    Chao T; Furth EE; Vonderheide RH
    Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
    Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
    Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
    J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
    Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
    PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
    Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
    Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.
    Balli D; Rech AJ; Stanger BZ; Vonderheide RH
    Clin Cancer Res; 2017 Jun; 23(12):3129-3138. PubMed ID: 28007776
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
    Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
    Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
    Vonderheide RH; Bear AS
    Front Immunol; 2020; 11():605619. PubMed ID: 33304355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
    Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
    Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
    Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH
    Cancer Cell; 2012 Jun; 21(6):822-35. PubMed ID: 22698406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
    Daniel SK; Sullivan KM; Labadie KP; Pillarisetty VG
    Clin Transl Med; 2019 Apr; 8(1):10. PubMed ID: 30931508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.